SEARCH

SEARCH BY CITATION

References

  • 1
    Soriano V, Puoti M, Sulkowski M et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. Aids 2007; 21: 7389.
  • 2
    Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Viral hepatitis and HIV co-infection. Antiviral Res 2010; 85: 315.
  • 3
    Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural-history of hepatitis-C virus-infection in multitransfused hemophiliacs – effect of coinfection with human-immunodeficiency-virus. J Acquir Immune Defic Syndr Hum Retrovirol 1993; 6: 210.
  • 4
    Fishbein DA, Lo YT, Netski D, Thomas DL, Klein RS. Predictors of hepatitis C virus RNA levels in a prospective cohort study of drug users. Jaids J Acquir Immune Defic Syndr 2006; 41: 7176.
  • 5
    Lesens O, Deschenes M, Steben M, Belanger G, Tsoukas CM. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 1999; 179: 254258.
  • 6
    Rockstroh JK, Mocroft A, Soriano V et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192: 921002.
  • 7
    Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. Aids 2004; 18: 3945.
  • 8
    Mocroft A, Soriano V, Rockstroh J et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? Aids 2005; 19: 117125.
  • 9
    Weber R. Liver-related deaths in persons infected with the human immunodeficiency virus – The D : A : D study. Arch Intern Med 2006; 166: 632641.
  • 10
    Weis N, Lindhardt BO, Kronborg G et al. Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a Nationwide Cohort Study. Clin Infect Dis 2006; 42: 481487.
  • 11
    Soriano V, Garcia-Samaniego J, Rodriguez-Rosado R, Gonzalez J, Pedreira J. Hepatitis C and HIV infection: biological, clinical, and therapeutic implications. J Hepatol 1999; 31: 119123.
  • 12
    Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 3850.
  • 13
    McCarthy JJ, Li JH, Thompson A et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 307314.
  • 14
    Herrero-Martinez E, Sabin CA, Evans JG, Griffioen A, Lee CA, Emery VC. The prognostic value of a single hepatitis C virus RNA load measurement taken early after human immunodeficiency virus seroconversion. J Infect Dis 2002; 186: 7076.
  • 15
    Thomas DL, Astemborski J, Vlahov D et al. Determinants of the quantity of hepatitis C virus RNA. J Infect Dis 2000; 181: 4451.
  • 16
    Yeo AET, Ghany M, Conry-Cantilena C et al. Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. J Viral Hepat 2001; 8: 5663.
  • 17
    Eyster ME, Fried MW, Dibisceglie AM, Goedert JJ. Increasing hepatitis-C virus-rna levels in hemophiliacs – relationship to human-immunodeficiency-virus infection and liver-disease. Blood 1994; 84: 020023.
  • 18
    Mocroft A, Ledergerber B, Katlama C et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 29.
  • 19
    Soriano V, Mocroft A, Rockstroh J et al. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 2008; 198: 337344.
  • 20
    Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C Virus transmission? Hepatology 2010; 52: 497505.
  • 21
    Hollingsworth RC, Sillekens P, vanDeursen P, Neal KR, Irving WL. Serum HCV RNA levels assessed by quantitative NASBA(R): stability of viral load over time, and lack of correlation with liver disease. J Hepatol 1996; 25: 0106.
  • 22
    Chen Y. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-a and ribavirin. Aliment Pharmacol Ther 2012; 36: 1103.
  • 23
    Peters L, Grint D, Lundgren JD et al. Chronic Hepatitis C (HCV) Infection and Chronic Kidney Disease (CKD) in HIV-infrected Patients in the EuroSIDA Study. 13th European Aids Conference (EACS). Belgrade, Serbia, October 2011 [Abstract PS7/3].
  • 24
    Mocroft A, Neuhaus J, Peters L et al. for the INSIGHT SMART and ESPRIT Study Groups. Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. PLoS ONE 2012; 7: e40245.
  • 25
    Thompson AJ, Muir AJ, Sulkowski MS et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 20U178.
  • 26
    Bower WA, Culver DH, Castor D et al. Changes in hepatitis C virus (HCV) viral load and interferon-alpha levels in HIV/HCV-coinfected patients treated with highly active antiretroviral therapy. Jaids J Acquir Immune Defic Syndr 2006; 42: 9397.
  • 27
    Rutschmann OT, Negro F, Hirschel B, Hadengue A, Anwar D, Perrin LH. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 1998; 177: 8385.
  • 28
    Chung RT, Evans SR, Yang YJ et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. Aids 2002; 16: 915923.
  • 29
    Rohrbach J, Robinson N, Harcourt G et al. Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut 2010; 59: 252258.
  • 30
    Cooper C. Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection. Clin Infect Dis 2002; 35: 7379.
  • 31
    Konopnicki D, Mocroft A, de Wit S et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. Aids 2005; 19: 93601.
  • 32
    Martin-Carbonero L, Barreiro P, Jimenez-Galan G, Garcia-Berriguete R, Nunez M. Clearance of hepatitis C virus in HIV-infected patients with multiple chronic viral hepatitis. J Viral Hepat 2007; 14: 9295.